Prevention of COVID-19 in Thoracic Surgery Patients: Lessons Learned during the First Pandemic Wave

Abstract

Background The aim of this retrospective study was to investigate the implementation of measures to prevent perioperative COVID-19 in thoracic surgery during the first wave of the COVID-19 pandemic 2020 allowing a continued surgical treatment of patients.

Methods The implemented preventive measures in patient management of the thoracic surgery department of the Asklepios Lung Clinic Munich-Gauting, Germany were retrospectively analyzed. Postoperative COVID-19 incidence before and after implementation of preventive measures was investigated. Patients admitted for thoracic surgical procedures between March and May 2020 were included in the study. Patient characteristics were analyzed. For the early detection of putative postoperative COVID-19 symptoms, typical post-discharge symptomatology of thoracic surgery patients was compared to non-surgical patients hospitalized for COVID-19.

Results Thirty-five surgical procedures and fifty-seven surgical procedures were performed before and after implementation of the preventive measures, respectively. Three patients undergoing thoracic surgery before implementation of preventive measures developed a COVID-19 pneumonia post-discharge. After implementation of preventive measures, no postoperative COVID-19 cases were identified. Fever, dyspnea, dry cough and diarrhea were significantly more prevalent in COVID-19 patients compared to normally recovering thoracic surgery patients, while anosmia, phlegm, low energy levels, body ache and nausea were similarly frequent in both groups.

Conclusions Based on the lessons learned during the first pandemic wave, we here provide a blueprint for successful easily implementable preventive measures minimizing SARS-CoV-2 transmission to thoracic surgery patients perioperatively. While symptoms of COVID-19 and the normal postoperative course of thoracic surgery patients substantially overlap, we found dyspnea, fever, cough, and diarrhea significantly more prevalent in COVID-19 patients than in normally recovering thoracic surgery patients. These symptoms should trigger further diagnostic testing for postoperative COVID-19 in thoracic surgery patients.

Zusammenfassung

Hintergrund Ziel dieser retrospektiven Studie war die Untersuchung von Maßnahmen zur Prävention perioperativer COVID-19-Erkrankungen bei fortgesetztem Vollbetrieb der Thoraxchirurgie während der ersten Welle der COVID-19-Pandemie 2020.

Methoden Es erfolgte eine retrospektive Analyse von eingesetzten Präventionsmaßnahmen in der Abteilung für Thoraxchirurgie der Asklepios Lungenklinik München-Gauting. Hierzu wurde die Inzidenz postoperativer COVID-19-Erkrankungen vor und nach der Einführung der Präventionsmaßnahmen ausgewertet. Patienten mit thoraxchirurgischen Operationen zwischen März und Mai 2020 wurden in die Studie eingeschlossen. Durch den Vergleich der postoperativen Symptome thoraxchirurgischer Patienten mit Symptomen von COVID-19-Patienten wurden spezifische Symptome zur Früherkennung der postoperativen COVID-19-Erkrankung identifiziert.

Ergebnisse Vor Einführung der Präventionsmaßnahmen erfolgten 35 thoraxchirurgische Operationen innerhalb von 22 Tagen während hoher COVID-19-Prävalenz im Einzugsgebiet der Klinik. Nach Einführung der Präventionsmaßnahmen erfolgten 57 thoraxchirurgische Eingriffe innerhalb von 54 Tagen. Vor Umsetzung der Präventionsmaßnahmen entwickelten 3 Patienten postoperativ eine COVID-19-Pneumonie. Nach Umsetzung zeigte sich kein postoperativer COVID-19-Fall. Fieber, Atemnot, trockener Husten und Durchfall waren bei an COVID-19 erkrankten Patienten signifikant häufiger als bei thoraxchirurgischen Patienten mit regelhaftem postoperativem Verlauf. Anosmie, Auswurf, Abgeschlagenheit, Gliederschmerzen und Übelkeit traten in beiden Gruppen ähnlich häufig auf.

Schlussfolgerungen Basierend auf unseren Erfahrungen in der ersten Pandemiewelle bieten wir eine Blaupause für erfolgreiche, leicht umzusetzende präventive Maßnahmen zur Minimierung des Risikos für eine perioperative COVID-19-Erkrankung bei thoraxchirurgischen Patienten. Wir konnten zeigen, dass Symptome einer postoperativen COVID-19-Pneumonie teilweise schwer von klassischen postoperativen Beschwerden abgrenzbar sind. Postoperative Dyspnoe, Fieber, Husten und Diarrhöen traten jedoch signifikant häufiger bei COVID-19-Erkrankten als im postoperativen Verlauf thoraxchirurgischer Patienten auf und sollten daher differenzialdiagnostisch an eine postoperative COVID-19-Erkrankung denken lassen.

Publication History

Received: 08 March 2021

Accepted: 09 June 2021

Article published online:
14 July 2021

• References

• 1 Wang D, Hu B, Hu C. et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA 2020;
• 2 Velavan TP, Meyer CG. The COVID-19 epidemic. Trop Med Int Health 2020; 25: 278-280
• 3 Stoleriu MG, Gerckens M, Hetrodt J. et al. Clinical course of three postoperative symptomatic Covid-19 cases in patients after lung lobectomy. Ann Thorac Surg 2020;
• 4 Nepogodiev D, Bhangu A, Glasbey JC. et al. Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study. The Lancet 2020; 396: 27-38
• 5 Garassino MC, Whisenant JG, Huang L-C. et al. COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study. Lancet Oncol 2020; 21: 914-922
• 6 Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet 2020; 395: 507-513
• 7 Huang J, Wang A, Kang G. et al. Clinical course of patients infected with severe acute respiratory syndrome coronavirus 2 soon after thoracoscopic lung surgery. J Thorac Cardiovasc Surg 2020; 160: e91-e93
• 8 Peng S, Huang L, Zhao B. et al. Clinical course of coronavirus disease 2019 in 11 patients after thoracic surgery and challenges in diagnosis. J Thorac Cardiovasc Surg 2020; 160: 585-592.e2
• 9 Sigel K, Wisnivesky JP. Comorbidity Profiles of Patients with Lung Cancer: A New Approach to Risk Stratification?. Ann Am Thorac Soc 2017; 14: 1512-1513
• 10 Antonoff M, Backhus L, Boffa DJ. et al. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. J Thorac Cardiovasc Surg 2020; 160: 601-605
• 11 Moon MR, Jones DR, Adams DH. et al. American Association for Thoracic Surgery: Maintaining the Mission during the COVID-19 Pandemic. J Thorac Cardiovasc Surg 2020;
• 12 Passaro A, Addeo A, von Garnier C. et al. ESMO Management and treatment adapted recommendations in the COVID-19 era: Lung cancer. ESMO Open 2020; 5: e000820
• 13 Hemingway JF, Singh N, Starnes BW. Emerging practice patterns in vascular surgery during the COVID-19 pandemic. J Vasc Surg 2020; 72: 396-402
• 14 Salenger R, Etchill EW, Ad N. et al. The Surge After the Surge: Cardiac Surgery Post-COVID-19. Ann Thorac Surg 2020; 110: 2020-2025
• 15 Riley JS, Luks VL, de Pina LF. et al. COVID-19 Pandemic Significantly Decreases Acute Surgical Complaints. Am Surg 2020; 86: 1492-1500
• 16 COVIDSurg Collaborative. Elective surgery cancellations due to the COVID-19 pandemic: global predictive modelling to inform surgical recovery plans. Br J Surg 2020; 107: 1440-1449
• 17 Moletta L, Pierobon ES, Capovilla G. et al. International guidelines and recommendations for surgery during Covid-19 pandemic: A Systematic Review. Int J Surg 2020; 79: 180-188
• 18 Fligor SC, Tsikis ST, Wang S. et al. Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review. J Thorac Dis 2020; 12: 6640-6654
• 19 Lai C-C, Shih T-P, Ko W-C. et al. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): The epidemic and the challenges. Int J Antimicrob Agents 2020; 55: 105924
• 20 Maringe C, Spicer J, Morris M. et al. The impact of the COVID-19 pandemic on cancer deaths due to delays in diagnosis in England, UK: a national, population-based, modelling study. Lancet Oncol 2020; 21: 1023-1034
• 21 Kluge S, Janssens U, Welte T. et al. S2k-Leitlinie – Empfehlungen zur stationären Therapie von Patienten mit COVID-19. Pneumologie 2021; 75: 88-112
• 22 Huang C, Wang Y, Li X. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395: 497-506
• 23 Zhou F, Yu T, Du R. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet 2020; 395: 1054-1062
• 24 Nie L, Dai K, Wu J. et al. Clinical characteristics and risk factors for in-hospital mortality of lung cancer patients with COVID-19: A multicenter, retrospective, cohort study. Thorac Cancer 2021; 12: 57-65
• 25 Tian J, Yuan X, Xiao J. et al. Clinical characteristics and risk factors associated with COVID-19 disease severity in patients with cancer in Wuhan, China: a multicentre, retrospective, cohort study. Lancet Oncol 2020; 21: 893-903
• 26 Grasselli G, Greco M, Zanella A. et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in Intensive Care Units in Lombardy, Italy. JAMA Intern Med 2020; 180: 1345-1355
• 27 Sturm R. Increases in morbid obesity in the USA: 2000-2005. Public Health 2007; 121: 492-496